Bilateral temporal-interference stimulation of the prefrontal cortex can improve working-memory capacity in healthy adults by eleven to fourteen percent across a six-week protocol. The adverse-event rates are low—headache in three percent of participants, tinnitus exacerbation in 1.2 percent—but the safety in broader populations remains uncharacterized because the Phase IIb trials excluded anyone with a pre-existing seizure disorder. Those numbers come from pooled results published last month by researchers at Imperial College London and EPFL, and they represent a genuine advance in non-invasive neuromodulation. They also represent the moment when a medical technology became a productivity tool before the medical framework could finish assessing it.
The science itself is not new. Temporal interference stimulation uses two high-frequency electric fields that pass harmlessly through the skull and interfere only at their intersection, producing a low-frequency envelope that modulates neural activity deep in the brain. Grossman and colleagues demonstrated the principle in 2017, and since then the technique has migrated from proof-of-concept to clinical pilot to, now, consumer readiness. A 2025 study in Human Brain Mapping showed that TI stimulation of the frontoparietal network reliably boosts working-memory performance, and a 2026 Psychophysiology paper traced the dorsolateral prefrontal cortex's specific role in cognitive control under TI. The mechanism is understood well enough that commercialization was always going to follow; what is striking is the speed and the framing.
Two startups, London-based Cerebrus Sound and San Francisco-based FocusLoop, have announced consumer-grade "cognitive endurance" headsets for the first quarter of 2027. Cerebrus is targeting knowledge-work firms with a B2B leasing model: employers pay per seat-month for employees to wear the device during high-demand tasks. FocusLoop is positioning its product as a "mental gym" subscription for individuals, but its enterprise pitch deck—leaked to TechCrunch—describes "attention yield management" dashboards that let managers correlate stimulation sessions with task-completion velocity. The broader wearable neurotech market is already attracting serious medtech investment, and these two entrants are betting that cognitive enhancement will follow the same enterprise-first path that fitness trackers and productivity software took before them.
The ethical frame is shifting from therapy to infrastructure. A Brookings Institution report published this month coins the term "attention leasing" to describe employer-controlled or employer-subsidized neural enhancement that effectively rents an employee's heightened focus during company time. The report notes that current US labor law does not clearly classify elective neural stimulation as either a medical benefit—regulated under HIPAA and the ACA—or a workplace surveillance tool—regulated under OSHA and the NLRA. That vacuum is not a temporary oversight; it is the space where a new industry is building its operating assumptions. The institution's earlier work on the future of work anticipated how technology would splinter labor markets into ever-smaller fragments with ever-larger scale economies, but the specific question of who owns the enhanced worker's attention during stimulation hours was not yet on the table.
The equity concern is equally sharp. A preliminary analysis by the Oxford Internet Institute suggests that if attention-leasing benefits are tax-deductible for employers but not employees, high-margin firms will capture cognitive gains first, widening performance gaps between well-capitalized and under-resourced sectors. The mechanism is straightforward: a consulting firm can lease a hundred headsets, deduct the cost, and measure the ROI in billable hours, while a public-school teacher or a nonprofit caseworker buys the same enhancement out of pocket with post-tax income, if they can afford it at all. The result is not just inequality of access but inequality of measured access, because the dashboards that quantify "attention yield" will become the performance metrics that determine promotions, bonuses, and job security.
The tension is not whether the technology works. The Phase IIb data say it does, within the narrow parameters of a controlled trial. The tension is what happens when the trial ends and the headset stays on, when the boundary between bodily autonomy and labor infrastructure dissolves not through coercion but through subscription pricing and tax incentives. If focus becomes a leased asset, the employer who pays for the lease has a plausible claim to the surplus focus it generates. The worker who accepts the lease, whether because it is mandatory, incentivized, or merely normalized, is no longer renting out their labor; they are renting out an altered version of their own nervous system. Whether labor law can catch up to that distinction before it becomes standard practice is an open question, and the answer may depend less on regulators than on whether the first wave of attention-leasing programs produce measurable returns.
Sources
– Grossman et al., "Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields," *Cell* (2017)
– Zheng et al., "Temporal Interference Stimulation Boosts Working Memory Performance in the Frontoparietal Network," *Human Brain Mapping* (2025)
– Chen et al., "The Distinct Roles of the Dorsolateral Prefrontal Cortex and Dorsal Anterior Cingulate Cortex in Cognitive Control: Evidence From Transcranial Temporal Interference Stimulation," *Psychophysiology* (2026)
– TechCrunch, "How a medtech market opportunity is shaping up for wearable neurotech" (2024)
– Brookings Institution, "The future of work" (2016)